Vanderbilt Hem/Onc shared a post on X:
“Dr. Shabnam Eghbali, PGY-2, Vanderbilt University Medical Center presented her work in metastatic Melanoma Society for Immunotherapy of Cancer SITC2024 treated with IO therapy:
- LILRB RNA expression = (+) prognostic biomarker.
- LILRB3 and LILRB4 leads to PFS/OS.”
